ArticleBMJ case reports2026
Subarachnoid haemorrhage during premenopausal dienogest therapy in a patient with multiple risk factors.
Article in BMJ case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We present the third case of subarachnoid haemorrhage (SAH) during dienogest (DNG) therapy documented in Japan. A woman in her 40s with a history of smoking and a family history of SAH developed a sudden severe headache and was diagnosed with SAH. Angiography revealed a ruptured anterior communicating artery aneurysm (9.4 mm), which was successfully treated with a Woven EndoBridge. DNG induces a hypooestrogenic state, with serum oestradiol levels dropping to 30 pg/mL after 1 year, potentially increasing the risk of aneurysm rupture. We revised our protocol accordingly to screen for SAH risk factors and perform magnetic resonance angiography (MRA) on patients with a relevant family history. Among the 120 patients screened, 10 patients had a family history of SAH and underwent MRA, which led to the detection of one unruptured aneurysm. DNG therapy was subsequently discontinued. These findings underscore the importance of assessing cerebral aneurysm risk before initiating DNG therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.